# US 2015/0086589 A1 · Virus-like particles comprising a matrix protein from a plant enveloped virus and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0086589 A1
- Document ID: US20150086589A1
- Status: Published application
- Kind: A1
- Application number: 14/379,408
- Filed: 2013-03-15
- Published: 2015-03-26
- Earliest claimed: 2012-03-22
- Assignees: Fraunhofer USA, Inc.
- Applicants: FRAUNHOFER USA Inc.
- Inventors: Alexei Prokhnevsky; Vidadi Yusibov
- Web page: https://patentgrep.com/patent/US20150086589A1

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/12: Viral antigens
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/8203: {Virus mediated transformation}
- C12N 15/8257: {for the production of primary gene products, e.g. pharmaceutical products, interferon}
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- A61K 2039/5258: {Virus-like particles}
- C07K 2319/02: containing a signal sequence
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16151: Methods of production or purification of viral material
- C12N 2760/16222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/20023: Virus like particles [VLP]
- C12N 2760/20041: Use of virus, viral particle or viral elements as a vector
- C12N 2770/00044: Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The present invention relates to novel virus-like particles (VLPs) comprising a matrix protein derived from a first plant enveloped virus and a surface polypeptide. The surface polypeptide comprises (a) a surface exposed portion derived from a target polypeptide (b) a transmembrane domain, and (c) a cytosolic tail derived from a transmembrane (e.g., glycoprotein) of a second plant enveloped virus. The target polypeptide may be antigenic or therapeutic. The first and the second plant enveloped viruses may be the same. Either plant enveloped virus may be a plant rhabdovirus. Also provided are methods of making and using the VLPs.

## Claims

### Claim 1

A virus-like particle comprising a matrix protein derived from a first plant enveloped virus and a surface polypeptide, wherein the surface polypeptide comprises
(a) a surface exposed portion derived from a target polypeptide,
(b) a transmembrane domain, and
(c) a cytosolic tail derived from a transmembrane protein of a second plant enveloped virus.

### Claim 2 (depends on 1)

The virus-like particle of claim 1, wherein the first plant enveloped virus and the second plant enveloped virus are the same.

### Claim 3 (depends on 1)

The virus-like particle of claim 1, wherein the virus-like particle is produced in a plant cell, a plant, or a portion of a plant.

### Claim 4 (depends on 1)

The virus-like particle of claim 1, wherein the first plant enveloped virus is a plant rhabdovirus.

### Claim 5 (depends on 4)

The virus-like particle of claim 4, wherein the plant rhabdovirus is selected from the group consisting of Lettuce Necrotic Yellows virus (LNYV), Northern Cereal Mosaic virus (NCMV), Sonhus Virus (SonV), and Broccoli necrotic yellows virus (BNYV).

### Claim 6 (depends on 1)

The virus-like particle of claim 1, wherein the surface exposed portion of the surface polypeptide is antigenic.

### Claim 7 (depends on 1)

The virus-like particle of claim 1, wherein the target polypeptide is derived from a pathogen.

### Claim 8 (depends on 1)

The virus-like particle of claim 1, wherein the surface exposed portion of the surface polypeptide is therapeutic.

### Claim 9 (depends on 1)

The virus-like particle of claim 1, wherein the target polypeptide is a native surface polypeptide.

### Claim 10 (depends on 1)

The virus-like particle of claim 1, wherein the target polypeptide is an artificial surface polypeptide.

### Claim 11 (depends on 1)

The virus-like particle of claim 1, wherein the transmembrane domain is native or foreign to the surface exposed portion.

### Claim 12 (depends on 1)

The virus-like particle of claim 1, wherein the transmembrane domain is derived from the transmembrane protein.

### Claim 13 (depends on 1)

The virus-like particle of claim 1, wherein the transmembrane domain is derived from a cellular or viral transmembrane protein.

### Claim 14

A method of producing virus-like particles in a plant cell, a plant or a portion of a plant, comprising
(a) introducing one or more nucleic acid molecules into the plant cell, the plant or the portion of a plant, wherein the one or more nucleic acid molecules comprise a first nucleotide sequence encoding a matrix protein derived from a first plant enveloped virus and a second nucleotide sequence encoding a surface polypeptide, wherein the surface polypeptide comprises
(i) a surface exposed portion derived from a target polypeptide,
(ii) a transmembrane domain, and
(iii) a cytosolic tail derived from a transmembrane protein of a second plant enveloped virus; and
(b) maintaining the plant cell, the plant or the portion of a plant under conditions permitting co-expression of the matrix protein and the surface polypeptide, whereby the virus-like particles are produced.

### Claim 15 (depends on 14)

The method of claim 14, wherein the first plant enveloped virus and the second plant enveloped virus are the same.

### Claim 16 (depends on 14)

The method of claim 14, wherein the virus-like particles are substantially uniform in size.

### Claim 17 (depends on 14)

The method of claim 14, further comprising (c) purifying the virus-like particles.

### Claim 18 (depends on 14)

The method of claim 14, wherein the one or more nucleic acid molecules are introduced into the plant cell, the plant or the portion of a plant by infiltration, particle bombardment, or inoculation.

### Claim 19 (depends on 14)

The method of claim 14, wherein the one or more nucleic acid molecules are introduced into the plant cell, the plant or the portion of a plant transiently or stably.

### Claim 20 (depends on 1)

An immunogenic composition comprising an effective amount of the virus-like particles of claim 1, wherein the virus-like particles are substantially uniform in size.

### Claim 21 (depends on 14)

An immunogenic composition comprising an effective amount of the virus-like particles produced by the method of claim 14, wherein the virus-like particles are substantially uniform in size.

### Claim 22 (depends on 20)

The immunogenic composition of claim 20, further comprising an adjuvant or an excipient.

### Claim 23 (depends on 14)

A method of inducing a protective immune response to a pathogen in a subject, comprising administering to the subject an effective amount of the virus like particles produced by the method of claim 14, wherein the target polypeptide is derived from the pathogen, and wherein the virus-like particles are substantially uniform in size.

### Claim 24

A recombinant plant cell comprising one or more nucleic acid molecules, wherein the one or more nucleic acid molecules comprise a first nucleotide sequence encoding a matrix protein derived from a first enveloped virus and a second nucleotide sequence encoding a surface polypeptide, and wherein the surface polypeptide comprises
(a) a surface exposed portion derived from a target polypeptide,
(b) a transmembrane domain, and
(c) a cytosolic tail derived from a glycoprotein of a second enveloped virus.

### Claim 25 (depends on 24)

The recombinant plant cell of claim 24, wherein the first plant enveloped virus and the second plant enveloped virus are the same.

### Claim 26 (depends on 24)

A plant or a portion thereof comprising the plant cell of claim 24.
